MedTrace Logo

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

NCT00964171 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-08-28

Study results available
· View outcomes & findings →

Summary

RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in treating patients with metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Efavirenz 600mg

Sponsors & Collaborators

  • Institut Bergonié

    lead OTHER

Principal Investigators

  • Marianne Fonck, MD · Institut Bergonié

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00964171 on ClinicalTrials.gov